Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ETHINYL ESTRADIOL & ETONOGESTREL

All products: not a benefit

Other products in the same Health Canada class (G02B) — coverage varies; not interchangeable

  • Levonorgestrel (Kyleena): general benefit

Haloette · DIN 02520028 · 0.120mg & 0.015mg/24 hr · Slow Release Vag Ring

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Haloette · DIN 02520028 Manufacturer: Searchlight Pharma Inc.; listing date 2021-11-30 Health Canada: Marketed since 2021-09-29 · brand HALOETTE · ATC G02BB01 VAGINAL RING WITH PROGESTOGEN AND ESTROGEN · form Ring (slow-release) · route Vaginal · ingredients ETHINYL ESTRADIOL 2.7 MG, ETONOGESTREL 11.7 MG · company Searchlight pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100924 · Verify on the e-Formulary ↗ (DIN 02520028)

Source record
DIN 02520028: Haloette Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 681200004; group id 727; item number 1790; lccId None; manufacturer id SLP Source form: Slow Release Vag Ring; strength: 0.120mg & 0.015mg/24 hr Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $14.2120; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02520028 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100924
Interchangeable products
Nuvaring · DIN 02253186 · not recorded
Shortage status: active shortage (reported 2025-12-01, estimated to end 2026-07-31, last updated 2026-02-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02520028
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:12 Contraceptives) and how they are covered

Matched class: 68:12 Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ETONOGESTREL, LEVONORGESTREL 68:12 Contraceptives

LEVONORGESTREL

· 2 products · General benefit · strengths: 19.5mg, 52mg · Insert

ETONOGESTREL

· 1 products · General benefit · strengths: 68mg/Implant · ER Subdermal Implant

NORETHINDRONE ACETATE/ETHINYL ESTRADIOL & ETHINYL ESTRADIOL

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg/10mcg & 10mcg · Tab-28 Tab Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:12
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: conception control
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: DESOGESTREL & ETHINYL ESTRADIOL, DROSPIRENONE & ETHINYL ESTRADIOL DESOGESTREL & ETHINYL ESTRADIOL · General benefit • Conception control PM: https://pdf.hres.ca/dpd_pm/00077799.PDF; date NOV 20, 2024; DIN 02042479; fetched 2026-09-10 Product monograph DROSPIRENONE & ETHINYL ESTRADIOL · General benefit • Conception Control PM: https://pdf.hres.ca/dpd_pm/00080997.PDF; date 2025-07-07; DIN 02261723; fetched 2026-09-10 Product monograph ETHINYL ESTRADIOL & LEVONORGESTREL · General benefit (18), Off-Formulary Interchangeable, not an ODB benefit (2) 1 Indications TRIQUILAR (levonorgestrel and ethinyl estradiol) is indicated for: • Conception control 1.1 Pediatrics Pediatrics (˂16 years of age): Based on the data submitted and reviewed by Health Canada, Health Canada has authorized an indication in women of reproductive age. PM: https://pdf.hres.ca/dpd_pm/00081001.PDF; date 2025-07-07; DIN 00707503; fetched 2026-09-10 Product monograph NORETHINDRONE · Listed, not a benefit (1), General benefit (2) INDICATIONS AND CLINICAL USE MOVISSE Tablets are indicated for conception control. PM: https://pdf.hres.ca/dpd_pm/00085300.PDF; date JUL 10, 2026; DIN 02410303; fetched 2026-09-10 Product monograph NORGESTIMATE & ETHINYL ESTRADIOL · Listed, not a benefit (4), General benefit (6) Indications TRI-CIRA LOTM 21 and TRI-CIRA LOTM 28 (Norgestimate and Ethinyl Estradiol Tablets) are indicated for:  Conception control. 1.1. PM: https://pdf.hres.ca/dpd_pm/00081457.PDF; date 2025-08-21; DIN 02401967; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS NUVARING® (etonogestrel/ethinyl estradiol slow release vaginal ring) is indicated for: • Conception control 1.1 Pediatrics Pediatrics (˂18 years of age): The safety and efficacy of NUVARING in adolescents under the age of 18 have not been studied. Use of this product before menarche is not indicated. 1.2 Geriatrics Geriatrics: NUVARING has not been studied in postmenopausal women and is not indicated in this population. https://pdf.hres.ca/dpd_pm/00077755.PDF PM date: DEC 12, 2004 Source product: NUVARING; DIN 02253186; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Haloette · DIN 02520028 Shortage status: active shortage (reported 2025-12-01, estimated to end 2026-07-31, last updated 2026-02-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02520028

Check this DIN again

Other review policies

For Haloette: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026